How many clinical trials are tracked for MDS?

20 trials are tracked, 1 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

MDS

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for MDS

20 trials tracked for MDS: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 211 citations.

20Trials tracked

3Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 3 Phase 2 14 Phase 1 2 Other / NA 1

Phase 3 Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed · 211 cited
Phase 3 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed
Phase 3 APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Completed
Phase 2 Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) Completed
Phase 2 Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC Completed
Phase 2 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant Completed

Show 14 more trials

Phase 2 Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Completed
Phase 2 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed
Phase 2 Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Completed
Phase 2 Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed
Phase 2 Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Completed
Phase 2 SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Completed
Phase 2 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Completed
Phase 2 Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Completed
Phase 2 Allogeneic Transplantation From Related Haploidentical Donors Completed
Phase 2 Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy Completed
Phase 2 Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS Completed
Phase 1 Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function Completed
Phase 1 A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status Completed
N/A Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.